Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that data from the Phase 2b ANTHEM-UC study with icotrokinra in ulcerative colitis will be the focus of a brief oral ...

Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor 1 Filing ...

When design environments function seamlessly, engineers spend time engineering instead of wrestling with files or tools.

BNB surges past $900 to $920 following Franklin Templeton partnership. Strong institutional demand and market momentum hint ...

Traditional microbial expression systems can be advanced through improved plasmid replication, target gene transcription, ...

Phase 2 TOIVA trial successfully met recruitment target, enrolling 16 subjects at leading vascular anomaly centers; top-line data expected in mid-December 2025 Venous malformations are the most common ...

The U.S. military’s technical engineers begin their careers at Fort Leonard Wood during advanced individual training to learn ...

However, now, experience is the only differtiator; it’s not just about usability, it’s about how deeply a product understands ...

China’s CNNC has made its first major carbon-14 isotope export, boosting its role in the global nuclear medicine market.

Gemini normalized the inflammatory response at the cellular level in stage 3 and 4 CKD patients – – Gemini could potentially ...

In the second interim analysis, lung function was assessed from the first 24 subjects at 6 weeks. GRI-0621 treated patients demonstrated no worsening of forced vital capacity ("FVC”) at 6 weeks ...